Authors
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsThe combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.
Latest:
Dr Baz on AE Management Discussions in Multiple MyelomaRachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.
Latest:
Dr. Shroff on Genomic Landscape of CholangiocarcinomaRachna T. Shroff, MD, MS, discusses actionable targets in intrahepatic and extrahepatic cholangiocarcinoma.
Latest:
Dr. Ramchandren on the North American Results of the ECHELON-1 Study in Hodgkin LymphomaRadhakrishnan Ramchandren MD, associate professor, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, discusses the North American results of the ECHELON-1 study in Hodgkin lymphoma.
Latest:
Breast Cancer Chemoprevention: Targeting the Estrogen ReceptorNew strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS TrialTreating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Latest:
Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA StudyDr. Rafael Fonseca presents the primary results of the phase 3 AURIGA study, which demonstrates the significant improvement in MRD-negative conversion and progression-free survival with subcutaneous daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma post-transplant, shared at the 2024 International Myeloma Society Annual Meeting.
Latest:
Treatment Considerations and Sequencing in Multiple MyelomaThe expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.
Latest:
Dr. Raffaele Califano on Immunotherapy in Small-Cell Lung CancerRaffaele Califano, MD, consultant in medical oncology at the Christie NHS Foundation Trust and University Hospital of South Manchester, discuses the potential for immunotherapy in small-cell lung cancer (SCLC).
Latest:
Dr. Hassan on Immunotherapy in Malignant Pleural MesotheliomaRaffit Hassan, MD, head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute Center for Cancer Research discusses immunotherapy in malignant pleural mesothelioma.
Latest:
Dr. Induru Discusses Other Mutations in Lung CancerRaghava R. Induru, MD, medical oncologist, Levine Cancer Institute, discusses other mutations in lung cancer.
Latest:
Dr. Kudchadkar on Future Research Directions for Rare, Non-Melanoma Skin CancersRagini Kudchadkar, MD, discusses future research directions for patients with rare, non-melanoma skin cancers.
Latest:
Dr. Kudchadkar on the Biological Differences Between Ocular and Cutaneous MelanomaRagini R. Kudchadkar, MD, discusses the biological differences between ocular melanoma and cutaneous melanoma.
Latest:
Dr Aggarwal on the Activity of BXCL701 Plus Pembrolizumab in SCNC mCRPCRahul Aggarwal, MD, discusses key findings from a phase 2a trial evaluating the combination of BXCL701 and pembrolizumab in patients with metastatic castration-resistant prostate cancer with the small cell neuroendocrine cancer phenotype.
Latest:
Hypofractionated and Stereotactic Body Radiotherapy in Prostate CancerDespite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.
Latest:
Taking the Fast Track to Independence in OncologyRahul S. Shinde, DVM, PhD, reflects on his journey to realizing his dreams of operating his own laboratory and serving as a leader in scientific research.
Latest:
Dr. Tendulkar Discusses Post-Prostatectomy Radiation TherapyRahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.
Latest:
No Age Limit for Bone Marrow TransplantationAge is no longer a consideration when determining whether an older patient with blood cancer is a candidate for stem cell transplantation.
Latest:
Dr. Mudad on RELAY Trial for EGFR-Mutant NSCLCRaja Mudad, MD, FACP, discusses the RELAY trial and using doublet therapy to treat EGFR-mutant non–small cell lung cancer.
Latest:
Dr. Bannerji on the Toxicity Profile of Odronextamab in Non-Hodgkin LymphomaRajat Bannerji, MD, PhD, discusses the toxicity profile of odronextamab in non-Hodgkin lymphoma.
Latest:
Update on the Management of Pain in Patients With Advanced CancerIn the United States in 2010, it was estimated that there were more than 1.5 million new cancer cases and 569,490 deaths from cancer.
Latest:
Rajni Kannan on the Side Effects of Yervoy and ZelborafRajni Kannan discusses the importance patient education or managing the side effects associated ipilimumab and vemurafenib in metastatic melanoma.
Latest:
Genomics Studies Opening Up Fresh Options for CRC ResearchRaju Kucherlapati, PhD, serves as principal investigator of a Genome Characterization Center as part of The Cancer Genome Atlas program, a National Cancer Institute initiative aimed at defining the copy number changes and structural aberrations present in many different cancer types.
Latest:
Dr. Popat on Investigational Strategies for Belantamab Mafodotin–Related Keratopathy in Multiple MyelomaRakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.
Latest:
Dr. Boccia on Managing Adverse Events With CAR T-Cell TherapyRalph Boccia, MD, an oncologist at the Center for Cancer and Blood Disorders, associate clinical professor at Georgetown University, discusses managing adverse events associated with chimeric antigen receptor T-cell therapy.
